Search Results 21-30 of 7605 for SIADH

  1. Patient Stories - Sailendra G. Naidu, M.D. - Mayo Clinic

    Have 2X the impact! ... Make a gift that can go twice as far to advance healthcare research. Give Today.

  2. Patient Stories - Sikander Ailawadhi, M.D. - Mayo Clinic

    Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.

  3. Publications - Joseph H. Skalski, M.D. - Mayo Clinic

    Kanj AN, Skalski JH. Gut Mycobiome and Asthma. J Fungi (Basel). 2024 Mar 1; 10 (3) Epub 2024 Mar 01. View PubMed; Gupta VK, Rajendraprasad S, Ozkan M, ...

  4. https://www.mayoclinic.org/chinese_patient_consumer_faq.xml

  5. Publications - Palak D. Shah, M.D., M.P.H. - Mayo Clinic

    Shah PD, Macpherson CC, Akpinar-Elci M. Impact of Undertreated Sickle Cell Pain in the Caribbean West Indies Medical Journal. 2014; 1:36-66.

  6. Safety Study Of SEA-CD40 In Cancer Patients - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  7. News - Tanios S. Bekaii-Saab, M.D. - Mayo Clinic

    Have 2X the impact! ... Make a gift that can go twice as far to advance healthcare research. Give Today.

  8. High Blood Pressure Clinical Trials - Mayo Clinic Research

    Early hypertension studies showed that treating elevated blood pressure (BP) reduces patients' risk of cardiovascular disease and all-cause mortality. In ...

  9. A Study of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction - Mayo Clinic

    Patients transferred in to an UPSTREAM hospital are eligible for inclusion, but the timing for OAP agent administration and diagnostic catheterization begin ...

  10. A Multi-center, Open-label Extension, Safety Study Of Mepolizumab In Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

    About this study. This is an open-label extension study to Study 200622.In this study subjects from Study 200622 will be continued on 4-weekly dosing with ...